SAN DIEGO, CA--(Marketwire - Apr 27, 2011) - Cytori Therapeutics (
Prior to the webcast at approximately 4:05 PM Eastern Time on May 5, Cytori will post a shareholder letter to its Investor Relations homepage, which will review Cytori's first quarter performance, provide an update on commercialization activities and discuss recent developments.
The webcast will be available both live and by replay two hours after the call on the Company's website, under "Webcasts" on the Investor Relations page (http://ir.cytoritx.com).
About Cytori
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures. www.cytori.com
Contact Information:
Contact:
Megan McCormick
mmccormick@cytori.com
858.875.5279